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ALF = acute liver failure; AoCLF = acute-on-chronic liver failure; CRRT = continuous renal replacement therapy; CVVHD = continuous veno-venous
haemodialysis; MARS = molecular adsorbents recirculating system.
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Abstract
The molecular adsorbents recirculating system (MARS®) is a form of artificial liver support that has the
potential to remove substantial quantities of albumin-bound toxins that have been postulated to
contribute to the pathogenesis of liver cell damage, haemodynamic instability and multi-organ failure in
patients with acute liver failure (ALF) and acute-on-chronic liver failure (AoCLF). These toxins include
fatty acids, bile acids, tryptophan, bilirubin, aromatic amino acids and nitric oxide. Data from controlled
clinical trials are limited so far. One of two studies performed on small numbers of patients with AoCLF
suggest a survival benefit, but no controlled data are available in the ALF setting. Our preliminary
experience with MARS therapy, instituted late in the clinical course of five patients with severely
impaired liver function, including three with AoCLF precipitated by sepsis and two with liver
dysfunction due to sepsis in the absence of pre-existing chronic liver disease, indicates some clinical
efficacy. However, the overall survival rate (1 of 5; 20%) remained poor. More data obtained from
larger cohorts of patients enrolled in randomised controlled studies will be required in both the AoCLF
and ALF settings to identify categories of liver failure patients who might benefit most from MARS
treatment, to ascertain the most appropriate timing of intervention and to determine the overall impact
on outcome, including cost-effectiveness.
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Introduction
The editors of the Health Technology Assessment Section of
Critical Care have facilitated the preparation article. This article
maintains our previous format for such reviews in which the
manufacturer provides answers to a standard questionnaire of
our own design and an independent early adopter describes
and reviews their own experiences using the device.
Carrying out and completing prospective studies of the
usefulness of new therapies is always a challenging task and
that is especially true for this device. It is also true that a
single intensive care unit is unlikely to be able to acquire a
large amount of experience using this liver support therapy
over a short period of time.
These articles are not able to resolve this dilemma, but they
do illustrate the real world difficulty in deciding when and
where to deploy a promising new technology at the bedside
when that technology is hard to test scientifically and its use
is both resource and labour intensive.281
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What is the science underlying the technology?
Molecular adsorbents recirculating system (MARS®) therapy
is a blood detoxification system based on albumin dialysis
that is able to remove albumin-bound and water-soluble
substances selectively. ‘Cleaning’ the body’s albumin pool
restores its ability to balance several systems in the body in
pathological situations.
What are the primary indications for its use?
• Primary and secondary liver failure/dysfunction
i. Primary:
a. Decompensated chronic liver disease 
(re-compensation/bridge to transplant)
b. Acute liver failure (recovery/bridge)
c. Liver failure after liver transplantation
ii. Secondary liver failure and multi-organ failure/dysfunction
What are the common secondary indications for its use?
• Intractable pruritus in cholestasis
• Liver failure after liver surgery
What are the efficacy data to support its use?
• Effective and selective removal of water-soluble and
albumin-bound substances [1] including nitric oxide
• Impact on neurological [2], hemodynamic [3,4], renal
[5,6] and other end-organ functions in liver failure [7,8]
• Decrease of oxidative stress [8]
Are there any appropriate outcome data available?
• Acute decompensated chronic liver disease [5]
• Hepato-renal syndrome [6]
• Overview of MARS-treated patients [9]
What are the costs of using the technology?
• The average number of treatments per therapy course is
three to five depending on the aetiology. The costs are on
average between 9000€ and 15,000€ for the therapy.
Should there be any special user requirements for the
safe and effective use of this technology?
• Hospital or non-hospital environment suitable for the
performance of extracorporeal blood therapy (comparable
to renal replacement therapy).
• Intensive care set-up if indicated by the patient’s
condition
What is the current status of this technology and, if it
is not in widespread use, why not?
• More than 4,500 patients have been treated in over
17,000 single treatments all over the world (status June
2004, Teraklin AG). Germany and Austria are the first
countries to have included MARS therapy into the
reimbursement catalogue (in-hospital therapy) 5 years
after introduction to the market in Europe. Reimbursement
is awaited as well in other European countries.
• FDA clearance has been applied for, and is pending.
What additional research is necessary or pending?
• Five multi-centre trials are on the way or planned in major
indications (Europe and the USA)





Martin Boyle, Jelica Kurtovic, David Bihari and Stephen Riordan
Introduction
The molecular adsorbents recirculating system (MARS) is a
form of artificial liver support therapy that has been available
for clinical use since 1998 and has been used in the
treatment of more than 3300 patients (more than 16,000
single treatments) [10]. MARS became available in Australia
in 2002. The Prince of Wales Hospital, Sydney, has a major
clinical and research interest in the management of patients
with liver failure and was interested to gain clinical experience
with MARS therapy. Here we briefly review the principles of
operation of the MARS device, the reported data on its
possible efficacy and our own preliminary experience
stemming from the introduction of this new technology into
our clinical practice.
MARS consists of an albumin haemodialyser, a standard
haemodialyser, an activated carbon adsorber and an anion
exchanger. This circuit is filled with 600 ml of 20% human
albumin solution. The albumin acts as a dialysate and is
pumped through a hollow-fibre membrane haemodialyser
(MARS Flux dialyser) countercurrent to the blood flow.
Protein-bound toxins and water-soluble substances diffuse
into the albumin solution. The albumin is then passed through
another dialyser countercurrent to a standard buffered
dialysis solution where diffusive clearance of water-soluble
substances occurs. The albumin solution is then cleaned of
its albumin-bound toxins by passage through an activated
carbon adsorber and an anion exchanger [11].
The MARS Flux dialyser has a surface area of 2.1 m2, a
membrane thickness of 100 nm and a molecular cut-off of
about 50 kDa. The irregularities in the membrane surface
provide deep crypts, which act as binding sites for albumin
when the circuit is primed with albumin solution. The albumin282
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molecules on the dialysis side of the membrane are in very
close proximity to the surface of the membrane in contact
with patient’s blood. Albumin-bound toxins move by
physicochemical interactions between the plasma, albumin
molecules bound to the dialysis side of the membrane and
the circulating albumin solution. A concentration gradient is
maintained by circulation of the albumin solution and disposal
of the albumin-bound toxins by passage through the activated
charcoal and anion-exchange columns [12,13].
MARS therapy has been shown to result in a relative
clearance of aromatic amino acids, leading to an improved
profile of branched-chain to aromatic amino acids and the
substantial removal of albumin-bound toxins such as fatty
acids, bile acids, tryptophan and bilirubin. The removal rates
of bilirubin and bile acids, for a single treatment, are about
28% and 55%, respectively [5,6,13–16]. The clearance of
bilirubin has been shown to decline over time with relatively
little clearance after about 6 hours of treatment, although
there is some contradictory evidence showing clearance to
be maintained at 5 hours [15,17]. Physiologically important
proteins (such as albumin, α1-glycoprotein, α1-antitrypsin, α2-
macroglobulin, transferrin and thyroxin-binding globulin) and
hormones (such as thyroxine and thyroid-stimulating
hormone) are not significantly removed [12].
Albumin contains reversible binding sites for substances
such as fatty acids, hormones, enzymes, dyes, trace metals
and drugs [12,13,18,19]. Albumin has a vital role in the
clearance from the body of substances that are toxic in the
unbound state by reversible binding and transport to the liver,
where they are metabolised and excreted into the biliary
system or in a water-soluble form by means of the kidneys
[13]. Albumin binds a number of substances that accumulate
in liver failure and have been implicated in the development of
hepato-renal syndrome, hepatic encephalopathy, haemo-
dynamic instability, ongoing liver injury and inhibition of liver
cell regeneration. It has been proposed that albumin binding
sites for these putative toxins become saturated in patients
with liver failure, consequent on decreased hepatic clearance,
leading to an accumulation of unbound toxic substances and
the development of organ dysfunction [13].
Rationale for MARS treatment in liver failure
In patients with liver failure it has been proposed that
clearance of albumin-bound toxins would create an
environment conducive to hepatocyte recovery and
regeneration, thereby allowing time for any superimposed
precipitant of hepatic decompensation, such as infection or
gastrointestinal bleeding, to be reversed and to delay or even
obviate the need for liver transplantation [13]. Such a
treatment is vital if mortality from acute liver failure (ALF) and
acute-on-chronic liver failure (AoCLF) is to be improved,
given the worldwide shortage of donor organs and the fact
that many patients listed for transplantation die while on
waiting lists, even with priority listing [20].
Experience with MARS in AoCLF
MARS treatment has been shown in the AoCLF setting to
significantly reduce plasma levels of the markers of albumin-
bound toxins, bilirubin and bile acids. Ammonia, a water-
soluble molecule, is also significantly cleared with MARS
therapy, as are the indices of uraemia control (urea and
creatinine) [5,6,13,15,16,21]. MARS has also been shown to
clear nitric oxide effectively [22].
Improvements in haemodynamic stability as indicated by
improved mean arterial pressure and a reduction in
requirement for vasopressor agents have been reported,
along with improvements in neurological state as measured
by the hepatic encephalopathy grade and intracranial pressure
[4,16,23,24]. Both in patients with AoCLF and in those with
otherwise well-compensated cirrhosis, MARS has been
reported to be used with some success in the treatment of
intractable pruritus resulting from intrahepatic cholestasis [25].
Only two small, randomised controlled trials have assessed
outcomes of MARS therapy compared with standard medical
therapy in patients with AoCLF. The first assessed the effect
of MARS in 13 patients with type I hepato-renal syndrome.
Eight patients received MARS in addition to renal replace-
ment and standard medical therapy, and five received renal
replacement and standard medical therapy. The MARS group
had a significant decrease in bilirubin level and an improved
prothrombin activity, and the 30-day mortality was 75% and
100% in the MARS and standard medical therapy groups,
respectively [6]. The second study assessed MARS in a group
of 24 patients with AoCLF: 12 patients received MARS
therapy and standard medical therapy, and the control group
received standard medical therapy only. The primary outcome
was a reduction and maintenance of serum bilirubin level to
less than 15 mg dl–1, while 30-day survival was a secondary
endpoint. In comparison with pretreatment values, the
bilirubin and bile acids decreased significantly in the MARS
group but not in the controls. At 30 days, one of 12 patients
receiving MARS had died, compared with 6 of 12 patients in
the control group. At interim analysis, the trial was stopped
on the recommendation of the institutional ethics committee,
to allow protocol revision so patients deteriorating on
standard medical therapy could have the opportunity to cross
over to MARS treatment [5].
Use of MARS in ALF
The data regarding the use of MARS in ALF are sparse,
consisting of small case series and case reports. No
controlled experiences have been reported. As in the AoCLF
setting, the use of MARS in ALF has been associated with
improvements in serum bilirubin and ammonia levels, together
with hepatic encephalopathy grade [26,27]. Several patients
have been successfully bridged, over several days, to
transplant [26–28]. MARS has been used in patients with a
range of aetiologies of ALF, including not only that due to
paracetamol overdose but other less common causes such283
as intoxication with Amanita phalloides [29,30]. MARS has
also been used in the treatment of primary graft dysfunction
after liver transplantation, with reports of success in bridging
to retransplantation along with instances of recovery of graft
function [27,28]. MARS has also been used to support
patients who develop liver failure after hemi-hepatectomy
[31,32].
The Prince of Wales Hospital experience with MARS
MARS became available for clinical use in Australia in 2002.
Since December 2002 we have used MARS to treat five
patients with severely impaired liver function, including three
with AoCLF precipitated by sepsis and two with liver
dysfunction due to sepsis in the absence of pre-existing
chronic liver disease. Patients received MARS therapy in
conjunction with parenteral antibiotics and full medical
intensive care measures. Clinical details of these patients are
presented in Table 1. Patients were selected for treatment
with MARS on the basis of failed medical therapy, with an
estimated mortality rate without intervention of more than
90%. Consequently, MARS therapy was introduced at an
advanced stage of the clinical course in each case. Indeed,
our five patients had higher Acute Physiology and Chronic
Health Evaluation (APACHE) II scores than those reported in
the available literature. All patients required mechanical
ventilatory support and were in acute renal failure, caused by
hepato-renal syndrome in three cases and sepsis-induced
acute tubular necrosis in two. Renal replacement therapy with
continuous veno-venous haemodialysis (CVVHD) was
required in three patients. Four of our patients required
vasopressor therapy (noradrenaline) to maintain a mean
arterial pressure of at least 70 mmHg. One patient (patient 5)
was on a waiting list for liver transplantation, and MARS was
instituted with the aim of bridging the patient until
complicating sepsis could be reversed and a donor liver
became available. Listing for transplantation was contra-
indicated by uncontrolled sepsis in the remaining four patients.
Intensive care unit nursing staff set up the MARS (ASC
BioTech Pty. Ltd., Sydney) circuit. These staff members were
familiar with the setting up and management of continuous
renal replacement therapy (CRRT). The set-up was
accomplished with little difficulty but was time-consuming,
taking about 2 hours to complete.
The planned duration of therapy in our patients ranged from 6
to 24 hours and was governed by haemodynamic status. The
recommended treatment regimens in the literature include
intermittent therapy over 6–8 hours in patients with a
relatively stable haemodynamic profile and continuous
therapy with circuit changes each 24 hours in unstable
patients. The albumin pump speed was maintained at
150 ml min–1 unless circuit pressures were excessive, in
which case the pump speed was reduced. CVVHD was used
for all treatments with dialysate flow rates ranging from 8.3 to
25 ml min–1 depending on the need for uraemia control.
Lactate-free dialysis fluid was used for all treatments.
Vascular access was gained with dual-lumen catheters
placed in the femoral or subclavian veins. Blood pump
speeds were set between 100 and 250 ml min–1 depending
on the quality of the vascular access and circuit pressures.
Anticoagulation of the extracorporeal circuit was achieved
with heparin alone or epoprostenol at 5 ng kg–1 min–1 plus
heparin. Heparin was adjusted to achieve an activated partial
thromboplastin time of about 50–60 s in blood drawn from
the patient. Only 6 of 12 treatments (50%) achieved the
prescribed duration of treatment. The early failure of one
circuit resulted from poor vascular access, whereas the




Parameter Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (years) 71 43 32 40 46
Gender M M F M F
APACHE II 33 30 34 25 31
Primary diagnosis AoCLF, 2o sepsis, Liver disease 2o to Liver disease 2o to AoCLF, 2o sepsis, AoCLF, 2o sepsis,
grade 4 HE, HRS sepsis, ATN sepsis, ATN grade 3 HE, HRS grade 3 HE, HRS
Background Cirrhosis (NASH) Post-hemihepatectomy Post-renal transplant Cirrhosis (HCV, Cirrhosis (HCV)
alcohol)
Child–Pugh Class C N/A N/A Class C Class C
Other treatment Ventilated, CVVHD, Ventilated, CVVHD, Ventilated, CVVHD Ventilated, CVVHD, Ventilated, CVVHD,
inotropes inotropes inotropes inotropes
AoCLF, acute-on-chronic liver failure; APACHE, Acute Physiology and Chronic Health Evaluation; CVVHD, continuous veno-venous haemodialysis;
HCV, hepatitis C virus; HE, hepatic encephalopathy; HRS, hepato-renal syndrome; NASH, non-alcoholic steatohepatitis; N/A, not applicable (no
pre-existing chronic liver disease).284
Clinical and biochemical data before and after MARS
therapy, along with survival data, are presented in Table 2.
Substantial reductions in the required dosage of nor-
adrenaline were documented in three of the four patients who
were vasopressor-dependent before MARS treatment.
Conversely, the noradrenaline dose increased from
0.06 µgk g –1 min–1 to 0.16 µgk g –1 min–1 in the other patient
(patient 2) in whom sepsis remained unresolved. Other
clinical and laboratory effects were similarly variable, although
improvement in hepatic encephalopathy grade was
documented in all three patients who were encephalopathic
before intervention. The serum creatinine level improved in all
three patients with hepato-renal syndrome but not in the two
with acute tubular necrosis. Patient 1 was the only patient to
show no improvement in the serum level of bilirubin but did
demonstrate improvements in urea, creatinine and ammonia,
along with improvements in haemodynamic status and
hepatic encephalopathy grade. Spur cell haemolytic anaemia,
consequent on severe liver damage, contributed to hyper-
bilirubinaemia in this patient and it is possible that the rate of
production of bilirubin exceeded removal capacity, even with
the MARS circuit. This explanation remains speculative
because we did not measure clearance of bilirubin in the
MARS dialysate. Nonetheless, a more marked increase in
hyperbilirubinaemia followed the cessation of MARS therapy,
lending weight to our hypothesis that at least some clearance
of bilirubin probably occurred during MARS treatment.
Patient 4 received the most MARS treatments, had the
lowest severity of illness score, and showed reductions in
creatinine, bilirubin and bile acids, and an improvement in the
arterial ketone body ratio. This was the only patient who
eventually survived to be discharged home.
Although our experience so far is only small, several
qualitative observations as early adopters of MARS treatment
in Australia are apparent. First, MARS treatment is a
technically feasible therapeutic option for liver support in the
general intensive-care setting. However, the set-up is labour
intensive by comparison with CRRT. As with CRRT, vascular
access seems to be a key factor in achieving the prescribed
treatment dose. Vascular access in patient 4 was obtained by
two double-lumen catheters. Both lumens of the internal
jugular vein catheter and femoral vein catheter were used for
outward blood flow and return blood flow respectively. This
will be our standard practice in the future. Second, when
haemodynamic status allows, we would favour shorter
treatment times of 6–8 hours duration with albumin flow rates
of at least 200 ml min–1 to reduce circuit failures resulting
from clotting and to reduce the need for prolonged use of
anti-coagulants. If patients are receiving CRRT, this can be
maintained during MARS treatment and continued after it has
been completed. Last, it is likely that MARS treatment was
instituted too late in the clinical course of our patients for a
realistic improvement in their chance of survival. Despite
many thousand reported treatment applications over the past
6 years, selection criteria for MARS therapy remain ill-defined.
This is due at least in part to the fact that most treatments
have been delivered in an uncontrolled fashion and in many
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Table 2
Clinical and laboratory effects of MARS therapy
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Parameter Normal range Before After Before After Before After Before After Before After
Noradrenaline, 0.22 0.02 0.06 0.16 0 0 0.22 0.10 0.32 0.06
µgk g –1 min–1
Creatinine 60–110 µM 307 142 132 239 171 234 241 144 164 107
Urea 2.9–7.1 mM 21 13 16 22 1 6 11 29 15 17
Ammonia 15–50 µM6 7 4 7
HE grade 4 3 3 1 3 2
Bilirubin <25 µM 161 210 654 528 260 182 484 137 510 326
Bile acids 0–6 µM 75 75 27 16 202 67
AA/β-OH-But 4.2 6.8 1.3 8 4 4.5
PDR ICG >16% min–1 4.4 5.5 4.3 5.2 4.3 5.4 5.6 5.2
Duration of 24, 16 15, 13 5, 6 12, 16, 20 6, 6, 6
treatment, h
Outcome ICU D/C, Died in ICU ICU D/C, D/C home Died in ICU
died in ward died in ward
AA/β-OH-But, ratio of arterial acetoacetate to β-hydroxybutyrate (ketone body); D/C, discharged; HE, hepatic encephalopathy; ICU, intensive care
unit; PDR ICG, plasma disappearance rate of indocyanine green (measured after an intravenous dose of 0.5 mg kg–1 body weight with a non-
invasive transcutaneous probe [Pulsion Medical System AG, Munich]).285
diverse clinical settings and treatment centres. Outcome
measures have similarly not been uniform. Further
randomised controlled studies using standardised inclusion
and exclusion criteria and outcome measures are urgently
required so that those categories of liver failure patients who
might benefit most from MARS therapy and those that can
confidently be managed by medical means alone can be
identified by the treating intensivist at a relatively early stage
in their clinical course, thereby maximising the chance of a
successful outcome.
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